Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00186992 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Radiation Therapy to Treat Musculoskeletal Tumors

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv42
  2. Results first posted: Mar 6, 2025 Primary endpoints revised (2) · Secondary endpoints revised (3)v41 Show 2 more changesShow less
    • Primary endpoints revised (2)
    • Secondary endpoints revised (3)

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date changed from estimate of Oct 2024 to Sep 15, 2023 Completion date: Oct 2024 to Oct 2029v40 Show 1 more changeShow less
    • Completion date: Oct 2024 to Oct 2029
  4. 4 versions Re-verified since Apr 4, 2022, no change to tracked fieldsv36-v39
  5. Primary and study completion dates: Jan 2024 to Oct 2024v35
Show 33 earlier versionsHide 33 earlier versions
  1. 3 versions Re-verified since Nov 15, 2018, no change to tracked fieldsv32-v34
  2. Enrollment target: 199 to 202 Primary and study completion dates: Jan 31, 2024 to Jan 2024v31 Show 1 more changeShow less
    • Primary and study completion dates: Jan 31, 2024 to Jan 2024
  3. Enrollment target: estimated 280 to confirmed 199v30
  4. Interventions: image-guided radiotherapy (Procedure) to image-guided radiotherapy (Radiation)v29
  5. Primary and study completion dates: Jan 2024 to Jan 31, 2024 Start date: Jan 2003 to Jan 10, 2003v28 Show 1 more changeShow less
    • Start date: Jan 2003 to Jan 10, 2003
  6. 2 versions Re-verified since Jul 24, 2015, no change to tracked fieldsv26-v27
  7. Trial status: Recruiting to Active, Not Recruiting Site details revisedv25 Show 1 more changeShow less
    • Site details revised
  8. Primary completion date: Jan 2019 to Jan 2024v24
  9. Eligibility criteria revised Study description shortened, about 18 wordsv23 Show 1 more changeShow less
    • Study description shortened, about 18 words

    See this version in full on ClinicalTrials.gov ↗

  10. Collaborators expanded, about 3 wordsv22 See this version in full on ClinicalTrials.gov ↗
  11. Primary completion date: Oct 2013 to Jan 2019 Primary endpoints revised (2) · Completion date: Oct 2028 to Jan 2024 · Secondary endpoints expanded, about 68 wordsv21 Show 3 more changesShow less
    • Primary endpoints revised (2)
    • Completion date: Oct 2028 to Jan 2024
    • Secondary endpoints expanded, about 68 words

    See this version in full on ClinicalTrials.gov ↗

  12. Enrollment target: 210 to 280 Completion date: Oct 2017 to Oct 2028 · Interventions: Delivery of conformal limited margin radiotherapy (Procedure) to image-guided radiotherapy (Procedure) · Eligibility criteria expanded, about 38 words · 1 morev20 Show 4 more changesShow less
    • Completion date: Oct 2017 to Oct 2028
    • Interventions: Delivery of conformal limited margin radiotherapy (Procedure) to image-guided radiotherapy (Procedure)
    • Eligibility criteria expanded, about 38 words
    • Study description expanded, about 57 words

    See this version in full on ClinicalTrials.gov ↗

  13. Collaborators shortened, about 3 wordsv19 See this version in full on ClinicalTrials.gov ↗
  14. Primary completion date: Oct 2011 to Oct 2013v18
  15. Re-verified, no change to tracked fieldsv17
  16. Completion date: Oct 2013 to Oct 2017v16
  17. Eligibility criteria expanded, about 181 words Study description expanded, about 292 wordsv15 Show 1 more changeShow less
    • Study description expanded, about 292 words

    See this version in full on ClinicalTrials.gov ↗

  18. Primary completion date: Dec 2010 to Oct 2011 Completion date: Dec 2010 to Oct 2013v14 Show 1 more changeShow less
    • Completion date: Dec 2010 to Oct 2013
  19. 3 versions Re-verified since Dec 2, 2008, no change to tracked fieldsv11-v13
  20. Primary completion date: Dec 2010v10
  21. Study arms: 0 to 1v9
  22. Enrollment target: 110 to 210 Completion date: Dec 2010 · Interventions: Brachytherapy (Procedure), Radiotherapy (Procedure) to Delivery of conformal limited margin radiotherapy (Procedure) · Publications: 1 to 8 · 1 morev8 Show 4 more changesShow less
    • Completion date: Dec 2010
    • Interventions: Brachytherapy (Procedure), Radiotherapy (Procedure) to Delivery of conformal limited margin radiotherapy (Procedure)
    • Publications: 1 to 8
    • Collaborators expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  23. Primary endpoints revised (2) Eligibility criteria expanded, about 2 wordsv7 Show 1 more changeShow less
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  24. Re-verified, no change to tracked fieldsv6
  25. Enrollment target: 100 to 110v5
  26. 3 versions Re-verified since Mar 7, 2006, no change to tracked fieldsv2-v4
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Researchers at St. Jude Children's Research Hospital are looking for more effective ways to deliver radiation therapy to pediatric tumors of the bone and soft tissues. The goal of the study is to improve local control of musculoskeletal tumors with image-guided radiation therapy (IGRT) while minimizing radiation related side effects. IGRT uses computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) images to precisely define tumor location and to carefully plan radiation treatment. This approach allows doctors to deliver highly conformal radiation therapy to the tumor while protecting nearby healthy normal tissues.
Trial Details
NCT Number NCT00186992
Lead Sponsor St. Jude Children's Research Hospital
Collaborators: Lance Armstrong Foundation
Conditions Sarcoma, Ewing's, Rhabdomyosarcoma, Soft Tissue Sarcoma, Musculoskeletal Tumors
Enrollment 202 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov